

Synthon Announces Strategic Expansion in Spain

Acquisition of adjacent site expands the footprint of Synthon Hispania, adding 6,000 m² of capacity to European development and manufacturing for complex generics

Sant Boi, Spain / Nijmegen, The Netherlands – Synthon, a global leader in the development and manufacturing of complex generic medicines, today announced a strategic expansion of its operations in Spain. The additional facility space is adjacent to its Sant Boi site.

The acquisition, which closed today, will add approximately 6,000 m² of expansion space to its current ~13,600m². The capacity will progressively be customized starting immediately, creating a flexible platform for additional future development and manufacturing. This investment further strengthens Synthon's commitment to European development and manufacturing. It enhances supply chain resilience to serve patients and partners across the region and globally.

For over 26 years, Synthon has been developing and manufacturing high quality, complex oral solid dose generics at the Sant Boi facility. Since the initial site acquisition in 1998, the company has invested over €50 million, adding specialized technologies and increasing production and packaging capacities to meet the growing needs of its partners. Today, the site employs over 600 highly skilled colleagues and produces over 2.5 billion units annually. As demand for high quality, complex generics continues to increase, this acquisition forms an excellent platform to rapidly scale Synthon's capabilities and capacities.

Anish Mehta, CEO of Synthon, said:

"This expansion is an important step in strengthening our network with synergistic space to continue making strategic investments that advance our mission of enabling access to affordable medicines. Further, this investment represents a deliberate choice to build more capability and more capacity here in Europe — bringing advanced manufacturing technologies, high-skilled jobs, and secure supply closer to the patients we serve in the region."

Dani Gomez, General Manager, Synthon Spain, added:

"This is a landmark moment for our team in Spain. Beyond the new technologies and capacity, this expansion means more new skilled jobs and stronger local partnerships. It confirms Synthon Hispania's role as a centre of excellence within the global network and as a key contributor to Spain's pharmaceutical ecosystem."

About Synthon

Synthon is a vertically integrated, global leader in the development and manufacturing of complex oral solid and injectable generics. For over three decades, the Company has established a proven track record of launching differentiated, complex products at market formation. Synthon has a global footprint with direct presence in multiple countries, including research laboratories and manufacturing sites in Spain, the Czech Republic, Argentina, and Chile. Headquartered in the Netherlands, Synthon employs approximately 1,700 people and serves customers in around 100 countries.

With a strong portfolio of complex molecules and a differentiated intellectual property-driven development platform, Synthon is committed to its mission of enabling affordable medicines globally.

Follow us on LinkedIn.

For further information, please visit <https://www.synthon.com/>

Media Contact

For further information, please contact:

Synthon

Email: info@synthon.com

Tel: +31 24 372 77 00

Website: www.synthon.com